Skip to main content

Table 1 Comparison of general data between both groups (x±sd) [n(%)]

From: Cisplatin combined with capecitabine-induced chemotherapy for local nasopharyngeal carcinoma can improve the quality of life and reduce toxic and side effects

Classification Group A (n=66) Group B (n=70) t/χ2 value p value
Gender    0.471 0.492
 Male 31 (46.97) 37 (52.86)   
 Female 35 (53.03) 33 (47.14)   
 Age (years) 46.13±5.18 47.11±5.12 1.109 0.269
Nationality    0.737 0.390
 Han 54 (81.82) 61 (87.14)   
 Ethnic minorities 12 (18.18) 9 (12.86)   
T staging    0.377 0.828
 T1 0 (0.00) 0 (0.00)   
 T2 19 (28.79) 17 (24.28)   
 T3 22 (33.33) 24 (34.29)   
 T4 25 (37.88) 29 (41.43)   
N staging    0.430 0.933
 N0 9 (13.64) 11 (15.71)   
 N1 27 (40.91) 25 (35.71)   
 N2 18 (27.27) 21 (30.00)   
 N3 12 (18.18) 13 (18.57)   
Clinical staging    0.047 0.826
 Stage III 28 (42.42) 31 (44.29)   
 Stage IVa 38 (57.58) 39 (55.71)   
Pathological types    1.550 0.460
 Low differentiated squamous cell carcinoma 36 (54.55) 40 (57.14)   
 Undifferentiated carcinoma 28 (42.42) 25 (35.71)   
 Adenocarcinoma 2 (3.03) 5 (7.14)